Neurofibromatosis 1: Closing the GAP between mice and men

Current Opinion in Genetics and Development

Volumn 13, Issue 1, 2003, Pages 20-27

  Dasgupta, Biplab ^a   Gutmann, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFIBROMIN; RAS PROTEIN; TUMOR SUPPRESSOR PROTEIN;

CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; DROSOPHILA; HETEROZYGOSITY; HUMAN; NEUROFIBROMATOSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW;

EID: 0037310530     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(02)00015-1     Document Type: Review

References (42)

1. Friedman J.M. Epidemiology of neurofibromatosis type 1. Am. J. Med. Genet. 89:1999;1-6.
2. Gutmann D.H., Aylsworth A., Carey J.C., Korf B., Marks J., Pyeritz R.E., Rubenstein A., Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 278:1997;51-57.
3. Listernick R., Louis D.N., Packer R.J., Gutmann D.H. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann. Neurol. 41:1997;143-149.
4. Side L., Taylor B., Cayouette M., Conner E., Thompson P., Luce M., Shannon K. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N. Eng. J. Med. 336:1997;1713-1720.
5. Bajenaru M.L., Donahoe J., Corral T., Reilly K.M., Brophy S., Pellicer A., Gutmann D.H. Neurofibromatosis 1 (NF1) heterozygosity results in cell autonomous growth advantage for astrocytes. Glia. 33:2001;314-323.
6. Sherman L.S., Atit R., Rosenbaum T., Cox A.D., Ratner N. Single cell Ras-GTP analysis reveals altered ras activity in a single population of neurofibroma Schwann cells but not fibroblasts. J. Biol. Chem. 275:2000;30740-30745.
7. -/- cells. J. Biol. Chem. 276:2001;7240-7245.
8. Kim H.A., Ling B., Ratner N. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol. Cell. Biol. 17:1997;862-872.
9. The I., Hannigan G.E., Cowley G.S., Reginald S., Zhong Y., Gusella J.F., Hariharan I.K. Bernards A: Rescue of Drosophila NF1 mutant phenotype by protein kinase A. Science. 276:1997;791-794.
10. Guo H.F., The I., Hannan F., Bernards A., Zhong Y. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP-like neuropeptides. Science. 276:1997;795-798.
11. Moroo I., Tatsuno I., Uchida D., Tanaka T., Saito J., Saito Y., Hirai A. Pituitary adenylate cyclase activating peptide (PACAP) stimulates mitogen-activated protein kinase (MAPK) in cultured rat astrocytes. Brain Res. 795:1998;191-196.
12. +/- mouse neurons, supporting the notion that neurofibromin has additional functions in mammalian cells besides RAS regulation.
13. -/- Drosophila, but that this abnormality results from dysregulated RAS activity. These findings support the notion that neurofibromin may have both RAS-dependent and RAS-independent functions in Drosophila.
14. Rutkowski J.L., Wu K., Gutmann D.H., Boyer P.J., Legius E. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum. Mol. Genet. 12:2000;1059-1066.
15. Muir D., Neubauer D., Lim I.T., Yachnis A.T., Wallace M.R. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am. J. Pathol. 158:2001;501-513.
16. Perry A., Roth K.A., Banerjee R., Fuller C.E., Gutmann D.H. NF1 deletions in S-100 protein positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associates plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am. J. Pathol. 159:2001;57-61.
17. Kourea H.P., Orlow I., Scheithauer B.W., Cordon-Cardo C., Woodruff J.M. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am. J. Pathol. 155:1999;1855-1860.
18. Kourea H.P., Cordon-Cardo C., Dudas M., Leung D., Woodruff J.M. Expression of p27 (kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27 (kip) in malignant transformation of neurofibromas. Am. J. Pathol. 155:1999;1885-1891.
19. DeClue J.E., Heffelfinger S., Benvenuto G., Ling B., Li S., Rui W., Vass W.C., Viskochil D., Ratner N. Epidermal growth factor expression in neurofibromatosis type1-related tumors and NF1 animal models. J. Clin. Invest. 105:2000;1233-1241.
20. Side L., Taylor B., Cayouette M., Conner E., Thompson P., Luce M., Shannon K. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N. Eng. J. Med. 336:1997;1713-1720.
21. Side L.E., Emanuel P.D., Taylor B., Franklin J., Thompson P., Castleberry R.P., Shannon K.M. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood. 92:1998;267-272.
22. Birnbaum R.A., O'Marcaigh A., Wardak Z., Zhang Y.Y., Dranoff G., Jacks T., Clapp D.W., Shannon K.M. NF1 and Gmcsf interact in myeloid leukemogenesis. Mol. Cell. 5:2000;189-195.
23. Gutmann D.H., Donahoe J., Brown T., James C.D., Perry A. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol. Appl. Neurobiol. 26:2000;361-367.
24. Lau N., Feldkamp M.M., Roncari L., Loehr A.H., Shannon P., Gutmann D.H., Guha A. Loss of neurofibromin is associated with activation of Ras/MAPK and PI3K/AKT signaling in a neurofibromatosis 1 astrocytoma. J. Neuropathol. Exp. Neurol. 59:2000;759-776.
25. Kluwe L., Hagel C., Tatagiba M., Thomas S., Stavrou D., Ostertag H., von Deimling A., Mautner V.F. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J. Neuropathol. Exp. Neurol. 60:2001;917-920.
26. Li J., Perry A., James C.D., Gutmann D.H. Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. Neurology. 56:2001;885-890.
27. Gutmann D.H., Hedrick N.M., Li J., Nagarajan R., Perry A., Watson M.A. Comparative gene expression profile analysis of Neurofibromatosis1-associated and sporadic pilocytic astrocytomas. Cancer Res. 62:2002;2085-2091.
28. Lakkis M.M., Golden J.A., O'Shea S., Epstein J.A. Neurofibromin deficiency in mice causes excencephaly and is a modifier for Splotch neural tube defects. Dev. Biol. 212:1999;80-92.
29. Zhang Y., Vik T.A., Ryder J.W., Srour E.F., Jacks T., Shannon K., Clapp D.W. Nf1 regulates hematopoietic progenitor cell growth and Ras signalling in response to multiple cytokines. J. Exp. Med. 187:1998;1893-1902.
30. Gutmann D.H., Loehr A., Zhang Y., Kim J., Henkemeyer M., Cashes A. Haploinsufficiency for neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene. 18:1999;4450-4459.
31. +/- cells are not functionally equivalent to wild-type cells and may contribute to the pathogenesis of NF1-associated features.
32. ras and hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J. Exp .Med. 194:2001;57-69.
33. Costa R.M., Federov N.B., Kogan J.H., Murphu G.G., Stern J., Ohno M., Kucherlapati R., Jacks T., Silva A. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature. 415:2002;526-530.
34. Zhu Y., Romero M.I., Ghosh P., Ye Z., Charnay P., Rushing E.J., Marsh J.D., Parada L.F. Ablation of NF1 functions in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 15:2001;859-876.
35. +/- cells (e.g. mast cells).
36. Cichowski K., Shih T.S., Schmitt E., Santiago S., Reilly K., McLaughlin M.E., Roderick T.B., Bronson R.T., Jacks T. Mouse models of tumor development in neurofibromatosis type 1. Science. 286:1999;2172-2176.
37. Bajenaru M.L., Zhu Y., Hedrick N.M., Donahoe J., Parada L.F., Gutmann D.H. Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol. Cell. Biol. 22:2002;5100-5113 This report demonstrates that neurofibromin loss in maturing astrocytes is not sufficient for astrocytoma formation in the mouse. In this study, the authors employ multiple approaches to inactivating neurofibromin in astrocytes and find that Nf1 loss in type-1 astrocytes does not confer a neoplastic phenotype. These findings suggest that NF1-associated glioma formation may require additional cellular or genetic changes.
38. Vogel K.S., Kleese L.J., Velasco-Miguel S., Meyers K., Rushing E.J., Parada L.F. Mouse tumor model of neurofibromatosis type 1. Science. 286:1999;2176-2179.
39. ARF cooperate to induce multiple tumor phenotype. Oncogene. 21:2002;4978-4982.
40. +/- mice maintained on specific genetic backgrounds develop brain tumors whereas in other strains, brain tumor development is uncommon. These findings suggest that additional 'modifier' genes exist that influence tumorigenesis in the mouse.
41. Li H., Velasco-Miguel V., Vass C.W., Parada L.F., DeClue J.E. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res. 62:2002;4507-4513 This report describes the cooperative effect of EGFR expression and activation in Schwann cell tumor proliferation in mice developing MPNST. The authors find that EGFR overexpression is seen in both mouse and human MPNSTs, suggesting that additional signaling abnormalities conferred by the aberrant expression of EGFR impact on the pathogenesis of one of the malignant tumor types in NF1.
42. +/- mice, but are not prone to tumors. These findings suggest that neurofibromin-containing exon 23a contributes to learning and memory in mice, but has a limited role in tumor formation.